During the “information day” organized by the Association “Cosmetica Italia” last October it has arisen the hard sustainability of the term "HYPOALLERGENIC", even if supported by specific tests. Bio Basic Europe have been supporting for years now the need for a more correct claim to ensure the high tolerability of a cosmetic product. In vitro experimental protocols on cell cultures, increasingly characterized by a great reproducibility, confirm a high predictivity in respect of any unwanted reactions observed in vivo on the skin, and the assessments performed in vivo allow to further check whether a cosmetic product could be used by consumers with demanding dermatological characteristics. Based on these consolidated experiences Bio Basic Europe has developed an experimental protocol that allows to predict on a preliminary basis the pro-sensitizing potential of a cosmetic product through an in vitro test according to OECD 442e guidelines and, afterwards, through an in vivo dermatological test, to evaluate both the possible irritating action of the product tested with a 24h Patch test, and the appearance of any undesirable effects, even if not serious, at skin level, through a “in-use” test. These evaluations thus allow to define the product object of study as "delicate" and to ascertain any sensitization phenomena. BIO BASIC EUROPE S.r.l. In Vivo Safety Tests Responsible Dr.ssa Daniela Gandini BIO BASIC EUROPE S.r.l. In Vitro Tests Responsible Dr.ssa Eliana Regola BIO BASIC EUROPE S.r.l. Technical Director Dr. Claudio Angelinetta BIO BASIC EUROPE S.r.l. Managing Director Dr. Umberto Pianca